Innate Pharma SA ( (FR:IPH) ) just unveiled an announcement.
Innate Pharma announced on April 23, 2025, that it will regain its rights to the CD123 targeting ANKET® SAR443579 (SAR’579) /IPH6101, previously under a 2016 agreement with Sanofi, which will now focus on developing BCMA targeting ANKET® for autoimmune indications. Sanofi plans to make a strategic investment of up to €15 million in Innate Pharma, subject to market conditions, further strengthening their collaboration. This move aligns with both companies’ strategic priorities and positions Innate Pharma to continue advancing its ANKET® platform in oncology and beyond, potentially impacting its market positioning and stakeholder interests.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company leverages its proprietary ANKET® platform to create multi-specific NK Cell Engagers, Antibody Drug Conjugates (ADC), and monoclonal antibodies (mAbs) to target various tumor types. Innate Pharma collaborates with biopharmaceutical giants like Sanofi and AstraZeneca to accelerate research and development, benefiting patients worldwide. Headquartered in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq.
YTD Price Performance: -50.0%
Average Trading Volume: 1,075
Technical Sentiment Signal: Strong Buy
Current Market Cap: $164.3M
For detailed information about IPH stock, go to TipRanks’ Stock Analysis page.